SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

por Nielsen, Stine SF, Vibholm, Line K, Monrad, Ida, Olesen, Rikke, Frattari, Giacomo S, Pahus, Marie H, Højen, Jesper F, Gunst, Jesper D, Erikstrup, Christian, Holleufer, Andreas, Hartmann, Rune, Østergaard, Lars, Søgaard, Ole S, Schleimann, Mariane H, Tolstrup, Martin
Publicado 2021

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

por Vibholm, Line K, Nielsen, Stine SF, Pahus, Marie H, Frattari, Giacomo S, Olesen, Rikke, Andersen, Rebecca, Monrad, Ida, Andersen, Anna HF, Thomsen, Michelle M, Konrad, Christina V, Andersen, Sidsel D, Højen, Jesper F, Gunst, Jesper D, Østergaard, Lars, Søgaard, Ole S, Schleimann, Mariane H, Tolstrup, Martin
Publicado 2021

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity

por Rosás-Umbert, Miriam, Gunst, Jesper D., Pahus, Marie H., Olesen, Rikke, Schleimann, Mariane, Denton, Paul W., Ramos, Victor, Ward, Adam, Kinloch, Natalie N., Copertino, Dennis C., Escribà, Tuixent, Llano, Anuska, Brumme, Zabrina L., Brad Jones, R., Mothe, Beatriz, Brander, Christian, Fox, Julie, Nussenzweig, Michel C., Fidler, Sarah, Caskey, Marina, Tolstrup, Martin, Søgaard, Ole S.
Publicado 2022

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

por Gunst, Jesper D., Højen, Jesper F., Pahus, Marie H., Rosás-Umbert, Miriam, Stiksrud, Birgitte, McMahon, James H., Denton, Paul W., Nielsen, Henrik, Johansen, Isik S., Benfield, Thomas, Leth, Steffen, Gerstoft, Jan, Østergaard, Lars, Schleimann, Mariane H., Olesen, Rikke, Støvring, Henrik, Vibholm, Line, Weis, Nina, Dyrhol-Riise, Anne M., Pedersen, Karen B. H., Lau, Jillian S. Y., Copertino, Dennis C., Linden, Noemi, Huynh, Tan T., Ramos, Victor, Jones, R. Brad, Lewin, Sharon R., Tolstrup, Martin, Rasmussen, Thomas A., Nussenzweig, Michel C., Caskey, Marina, Reikvam, Dag Henrik, Søgaard, Ole S.
Publicado 2023

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

por Gunst, Jesper D., Staerke, Nina B., Pahus, Marie H., Kristensen, Lena H., Bodilsen, Jacob, Lohse, Nicolai, Dalgaard, Lars S., Brønnum, Dorthe, Fröbert, Ole, Hønge, Bo, Johansen, Isik S., Monrad, Ida, Erikstrup, Christian, Rosendal, Regitze, Vilstrup, Emil, Mariager, Theis, Bove, Dorthe G., Offersen, Rasmus, Shakar, Shakil, Cajander, Sara, Jørgensen, Nis P., Sritharan, Sajitha S., Breining, Peter, Jespersen, Søren, Mortensen, Klaus L., Jensen, Mads L., Kolte, Lilian, Frattari, Giacomo S., Larsen, Carsten S., Storgaard, Merete, Nielsen, Lars P., Tolstrup, Martin, Sædder, Eva A., Østergaard, Lars J., Ngo, Hien T.T., Jensen, Morten H., Højen, Jesper F., Kjolby, Mads, Søgaard, Ole S.
Publicado 2021